mAbs N-glycosylation: Implications for biotechnology and analytics

Area of Science:

• Biotechnology
• Immunology
• Biochemistry

Background:

• Monoclonal antibodies (mAbs) are highly successful therapeutics for cancer, immune disorders, and infections.
• Antibody N-glycosylation, a critical post-translational modification, significantly impacts mAb stability, half-life, and biological activity.
• Optimizing N-glycosylation is crucial for large-scale biopharmaceutical mAb production.

Purpose of the Study:

• To review recent advancements in producing glycoengineered monoclonal antibodies.
• To summarize novel methods for analyzing N-glycosylation in mAbs.
• To highlight the importance of N-glycosylation in therapeutic antibody development.

Main Methods:

• Production of mAbs in glycoengineered animal cell lines.
• Production of mAbs in glycoengineered plant-based systems.
• Production of mAbs in glycoengineered yeast cell lines.
• Development of novel analytical techniques for N-glycosylation analysis.

Main Results:

• Successful production of mAbs with tailored glycosylation profiles using glycoengineered systems.
• Demonstration of improved mAb stability, half-life, and efficacy through N-glycosylation engineering.
• Advancements in analytical methodologies enabling precise characterization of mAb N-glycosylation.

Conclusions:

• Glycoengineering offers a powerful strategy to optimize therapeutic mAbs.
• Diverse expression systems (animal, plant, yeast) are viable for producing engineered mAbs.
• Continued innovation in analytical techniques is essential for understanding and controlling mAb N-glycosylation.